Close menu
Open menu
Potential novel immuno-oncology mechanism revealed during translational Phase I immuno-blood profiling of experimental ADC medicine OBT076 in a gastric cancer patient.
Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results
Phase 1 study of OBT076, first in class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy and PK/PD results
Analysis of tumor infiltrating lymphocytes and in vitro exhausted T cell models to identify unique Immuno-Oncology targets
The use of proteomics to analyse whole tumors and identify unique stroma cell targets for antibody-based therapeutics
The use of proteomics to analyze whole tumors and identify unique immuno-oncology targets for antibody-based therapeutics
Proteomics and Selecting the Right Combination of Target and Toxin for Antibody-Drug-Conjugate (ADC) Development
Proteomics highlights which G-protein coupled receptors are candidates for ADC development